Department of Biotechnology and Nanomedicine, SINTEF Industry, Richard Birkelands vei 3B, N-7034 Trondheim, Norway.
Department of Biotechnology and Food Science, Norwegian University of Science and Technology, NTNU, Sem Sælands vei 6-8, N-7491 Trondheim, Norway.
Mar Drugs. 2020 Nov 18;18(11):565. doi: 10.3390/md18110565.
Alginates are one of the major polysaccharide constituents of marine brown algae in commercial manufacturing. However, the content and composition of alginates differ according to the distinct parts of these macroalgae and have a direct impact on the concentration of guluronate and subsequent commercial value of the final product. The mannuronan C-5 epimerases AlgE1 and AlgE4 were used to determine their potential value in tailoring the production of high guluronate low-molecular-weight alginates from two sources of high mannuronic acid alginates, the naturally occurring harvested brown algae (, and ) and a pure mannuronic acid alginate derived from fermented production of the mutant strain of NCIMB 10,525. The mannuronan C-5 epimerases used in this study increased the content of guluronate from 32% up to 81% in both the harvested seaweed and bacterial fermented alginate sources. The guluronate-rich alginate oligomers subsequently derived from these two different sources showed structural identity as determined by proton nuclear magnetic resonance (H NMR), high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) and size-exclusion chromatography with online multi-angle static laser light scattering (SEC-MALS). Functional identity was determined by minimum inhibitory concentration (MIC) assays with selected bacteria and antibiotics using the previously documented low-molecular-weight guluronate enriched alginate OligoG CF-5/20 as a comparator. The alginates produced using either source showed similar antibiotic potentiation effects to the drug candidate OligoG CF-5/20 currently in development as a mucolytic and anti-biofilm agent. These findings clearly illustrate the value of using epimerases to provide an alternative production route for novel low-molecular-weight alginates.
海藻酸盐是商业生产中海洋褐藻的主要多糖成分之一。然而,海藻酸盐的含量和组成因这些大型藻类的不同部位而有所不同,并且直接影响到古洛糖醛酸的浓度,进而影响最终产品的商业价值。使用甘露糖醛酸 C-5 差向异构酶 AlgE1 和 AlgE4 来确定它们在定制高古洛糖醛酸低分子量海藻酸盐生产中的潜在价值,这两种海藻酸盐均来自高甘露糖醛酸海藻酸盐的两个来源,即天然收获的褐藻( 、 和 )和源自突变株发酵生产的纯甘露糖醛酸海藻酸盐 NCIMB 10,525。本研究中使用的甘露糖醛酸 C-5 差向异构酶将收获的海藻和细菌发酵来源的海藻酸盐中的古洛糖醛酸含量从 32%提高到 81%。随后从这两个不同来源衍生出的富含古洛糖醛酸的海藻酸盐低聚物通过质子核磁共振( 1H NMR)、高效阴离子交换色谱与脉冲安培检测(HPAEC-PAD)和在线多角度静态激光散射(SEC-MALS)确定其结构同一性。通过使用先前报道的低分子量富含古洛糖醛酸的海藻酸盐寡糖 OligoG CF-5/20 作为比较物,用选定的细菌和抗生素进行最低抑菌浓度(MIC)测定,确定了功能同一性。使用这两种来源中的任何一种来源生产的海藻酸盐都显示出与目前作为黏液溶解剂和抗生物膜剂开发的候选药物 OligoG CF-5/20 相似的抗生素增效作用。这些发现清楚地表明,使用差向异构酶为新型低分子量海藻酸盐提供替代生产途径具有重要价值。